ParagonCare Limited reported a solid FY25 with $3.6 billion in revenue and $95.2 million underlying EBITDA, marking progress in its integration and growth strategy across Asia Pacific. The company is poised for further profitability improvements and expansion in FY26.
Paragon Care Limited reported a robust 22% increase in revenue to $3.61 billion for FY25, driven by organic growth and key acquisitions including CH2 Holdings and Oborne Health Supplies. The company also refinanced its debt facilities and expanded into the dental market post-year-end.
ParagonCare appoints Carmen Riley as CEO effective July 1, 2025, with a planned transition period under outgoing CEO David Collins to complete integration and pursue M&A opportunities.
Algorae Pharmaceuticals reports significant progress in its AI-driven drug discovery platform, unveiling 24 novel oncology targets and appointing a seasoned Chief Commercial Officer to bolster market readiness.
Sigma Healthcare has raised its FY25 normalised EBIT guidance to $64-$70 million, driven by robust operational performance and the successful rollout of a key supply contract with Chemist Warehouse.